Abstract
Introduction: The kynurenine pathway includes several neuroactive compounds, including kynurenic acid, picolinic acid, 3-hydroxykynurenine and quinolinic acid. The enzymatic cascade of the kynurenine pathway is tightly connected with the immune system, and may provide a link between the immune system and neurotransmission.
Main Areas Covered: Alterations in this cascade are associated with neurodegenerative, neurocognitive, autoimmune and psychiatric disorders, such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, migraine or schizophrenia.
Highlights: This review highlights the alterations in this metabolic pathway in the physiological aging process and in different disorders. A survey is also presented of therapeutic possibilities of influencing this metabolic route, which can be achieved through the use of synthetic kynurenic acid analogues, enzyme inhibitors or even nanotechnology.
Keywords: Aging, Alzheimer’s disease, amyotrophic lateral sclerosis, glutamate excitotoxicity, Huntington’s disease, kynurenine pathway, migraine, multiple sclerosis, neurodegeneration, neuroprotection, Parkinson’s disease, picolinic acid, schizophrenia, Toxoplasma gondii.
Current Drug Metabolism
Title:Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Volume: 17 Issue: 5
Author(s): Nóra Török, Zsófia Majláth, Ferenc Fülöp, József Toldi and László Vécsei
Affiliation:
Keywords: Aging, Alzheimer’s disease, amyotrophic lateral sclerosis, glutamate excitotoxicity, Huntington’s disease, kynurenine pathway, migraine, multiple sclerosis, neurodegeneration, neuroprotection, Parkinson’s disease, picolinic acid, schizophrenia, Toxoplasma gondii.
Abstract: Introduction: The kynurenine pathway includes several neuroactive compounds, including kynurenic acid, picolinic acid, 3-hydroxykynurenine and quinolinic acid. The enzymatic cascade of the kynurenine pathway is tightly connected with the immune system, and may provide a link between the immune system and neurotransmission.
Main Areas Covered: Alterations in this cascade are associated with neurodegenerative, neurocognitive, autoimmune and psychiatric disorders, such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, migraine or schizophrenia.
Highlights: This review highlights the alterations in this metabolic pathway in the physiological aging process and in different disorders. A survey is also presented of therapeutic possibilities of influencing this metabolic route, which can be achieved through the use of synthetic kynurenic acid analogues, enzyme inhibitors or even nanotechnology.
Export Options
About this article
Cite this article as:
Török Nóra, Majláth Zsófia, Fülöp Ferenc, Toldi József and Vécsei László, Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism, Current Drug Metabolism 2016; 17 (5) . https://dx.doi.org/10.2174/1389200217666151222155043
DOI https://dx.doi.org/10.2174/1389200217666151222155043 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulation of Angiogenesis by Th1- and Th2-Type Cytokines
Current Pharmaceutical Design Current Prodrug Design for Drug Discovery
Current Pharmaceutical Design P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Passive and Active Tumour Targeting with Nanocarriers
Current Drug Discovery Technologies Separation and Identification of Antibacterial Chamomile Components Using OPLC, Bioautography and GC-MS
Medicinal Chemistry Design and Virtual Screening Towards Synthesis of Novel Substituted Thiosemicarbozones as Ribonuleotide Reductase (RNR) Inhibitors with Improved Cellular Trafficking and Anticancer Activity
Current Topics in Medicinal Chemistry Polyisoprenylation Potentiates the Inhibition of Polyisoprenylated Methylated Protein Methyl Esterase and the Cell Degenerative Effects of Sulfonyl Fluorides
Current Cancer Drug Targets CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) The Induction and Repair of DNA Interstrand Crosslinks and Implications in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Feature Selection Using Information Distance Measure for Gene Expression Data
Current Proteomics New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Editorial (Thematic Issue: Chemical and Biological Technology for In Vivo and Molecular Imaging)
Current Topics in Medicinal Chemistry Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery